More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

Oregon Health & Science University is getting a major boost in its effort to better understand and eventually treat some of ...

A new drug that works against the main types of primary bone cancer has been developed by researchers at the University of ...

Myeloma is a cancer that affects specialised antibody-producing cells called plasma cells. Over your lifetime, your body ...

Confirming what many cancer specialists have long believed, British researchers have shown that high-dose chemotherapy and a stem cell transplant together are far more effective against the bone ...

Cellular therapies that harness a patient’s own immune system to identify and eliminate cancer cells are rapidly expanding ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Am J Health Syst Pharm. 2006;63(5):419-430. During resorption, growth factors and proteins released from osteoblast precursors and bone stimulate the differentiation, chemotaxis, and proliferation of ...

Researchers from UC Davis and Lawrence Livermore National Laboratory developed and studied a new material — engineered bone marrow, or eBM. Engineered bone marrow offers a better way to study ...